Printer Friendly

SCIOS INC. ANNOUNCES U.S. PATENT AWARDED FOR INSULINOTROPIN AS TREATMENT FOR TYPE II DIABETES

 SCIOS INC. ANNOUNCES U.S. PATENT AWARDED FOR INSULINOTROPIN
 AS TREATMENT FOR TYPE II DIABETES
 MOUNTAIN VIEW, Calif., July 9 /PRNewswire/ -- Scios Inc. (NASDAQ: SCIO) announced today that the U.S. Patent and Trademark Office has awarded patents (No. 5,120,712 and No. 5,118,666) covering the gastrointestinal hormone, insulinotropin, related compounds and their use as treatment for Type II diabetes. Scios has an exclusive worldwide license to the patents, which are owned by the Massachusetts General Hospital. Through a collaboration with Pfizer Inc., insulinotropin is undergoing Phase II clinical trials.
 "The patents which are the first to issue covering insulinotropin and related compounds, are the foundation of our proprietary position for this promising diabetes therapy," commented Richard L. Casey, Scios president and chief executive officer. "Insulinotropin represents a major new approach in treating Type II diabetes because it can control blood glucose without the risk of reducing it to dangerously low levels."
 The issued patents cover composition of matter for insulinotropin (glucagon-like peptide 1 (7-37) and related compounds, pharmaceutical products containing them and their use for the treatment of Type II diabetes. In Type II (non-insulin dependent) diabetes, insufficient insulin is secreted by the pancreas to properly regulate blood glucose levels. Early clinical studies demonstrate that insulinotropin stimulates the release of insulin from the pancreas, thus reducing blood sugar levels in patients with Type II diabetes. The studies also reveal that insulinotropin reduces blood sugar levels in a highly controlled manner that limits the risk of blood sugar levels becoming inappropriately low.
 The inventor named on the patents is Joel F. Habener, M.D., associate physician at the Massachusetts General Hospital, professor of medicine of Harvard Medical School, and the investigator of the Howard Hughes Medical Institute.
 Scios Inc. (formerly California Biotechnology Inc.) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios focuses its efforts in three areas: cardiopulmonary disease, tissue repair, and metabolic disorders. The company develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical companies.
 -0- 7/9/92
 /CONTACT: Virginia Walker of Scios, 415-940-6634 or 415-940-6631; or Martin Bander of Massachusetts General Hospital, 617-726-2206; or Lynne Brum of Feinstein Partners, 617-577-8110, for Scios/
 (SCIO) CO: Scios, Inc. ST: California, Massachusetts IN: MTC SU:


TM -- NE002 -- 7701 07/09/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 9, 1992
Words:390
Previous Article:SHOPKO STORES REPORTS JUNE SALES UP 4.4 PERCENT
Next Article:JUNE SALES UP 24.2 PERCENT AT Hi/LO AUTOMOTIVE
Topics:


Related Articles
SCIOS REPORTS FIRST QUARTER 1992 FINANCIAL RESULTS
SCIOS NOVA ANNOUNCES REDUCTION IN STAFF AS PART OF REFOCUSED STRATEGIC PLAN
SCIOS NOVA AND PFIZER RESTRUCTURE CORPORATE ALLIANCE
SCIOS NOVA CONSOLIDATES ITS RESEARCH AND DEVELOPMENT OPERATIONS
SCIOS NOVA RECEIVES U.S. PATENT FOR FIBLAST(TM) TROFERMIN (bFGF)
SCIOS ANNOUNCES CHANGE IN INSULINOTROPIN RELATIONSHIP
Novo Nordisk Acquires License from Scios for Insulinotropin
Chiron and Scios Announce $25 Million Licensing Agreement on FGF.
Chiron and Scios Announce Completion of Agreement on Human Basic Fibroblast Growth Factor.
Celtrix Receives Key U.S. Patent to Treat Diabetes.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters